Notice to convene Annual General Meeting
Apr 25, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on: Wednesday, May 17, 2023 at 11:00 AM (CEST) at the offices of Gorrissen Federspiel, Axeltorv 2, DK-1609 Copenhagen V.
Appendix 1 Candidates for the Board of Directors
Announcement Notice to convene AGM 2023
Read moreOrphazyme Announces Publication of 2022 Financial Results and Annual Report
Apr 25, 2023
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today announced its financial results for the period from January 1, 2022, to December 31, 2022, and publishes its Annual Report.
Announcement Annual Report 2022
Read moreChange to Financial Calendar for 2023 and update regarding class action lawsuit in United States
Apr 17, 2023
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), announces that publication of its financial results for the full year ending December 31, 2022, previously expected April 19, 2023, are now expected to be published on April 25, 2023. Additional time is required to conclude the presentation of the financial statements. The updated financial calendar for 2023 is available on the Company’s website.
Read moreOrphazyme reports financial results in Interim Report First Half 2022
Sep 26, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”) today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2022.
Orphazyme reports financial results in Interim Report First Half 2022
Orphazyme Interim Report H1 2022
Read moreAdjusted financial outlook for 2022
Sep 25, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”) has decided to adjust its outlook for 2022, as published on June 7, 2022.
Adjusted financial outlook for 2022
Read moreUpdated financial calendar for 2022
Sep 19, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022.
Updated Financial Calendar for 2022 H1 update
Read moreResolutions passed at the Annual General Meeting
Jun 29, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the Annual General Meeting
Read moreUpdated notice to holders of ADSs regarding termination of Deposit Agreement
Jun 20, 2022
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) representing deposited common shares of the Company regarding termination of the Deposit Agreement (the “Deposit Agreement”) dated September 28, 2020 among the Company, The Bank of New York Mellon, as depositary (the “the Depositary”), and Owners and ADR Holders (“ADR Holders”).
Updated notice to holders of ADSs regarding termination of Deposit Agreement
Read moreCorrection: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Jun 8, 2022
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
Correction Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Read moreNotice to convene Annual General Meeting
Jun 7, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on.
Appendix 1 Candidates for the Board of Directors 1
Notice to convene Annual General Meeting
Orphazyme Notice to convene AGM 2022
Read more